Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide plus Basal Insulin vs Basal-Bolus in Diabetic Kidney Disease
NCT05218915Phase 4Completed
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM). Started Jan 2022; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05218915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218915.